Strata Acquires Louisville Perfusion Services

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that it has completed the acquisition of Louisville Perfusion Services, Inc. (“LPS”), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky. “The acquisition of Louisville Perfusion Services fits perfectly with our existing customer base in Kentucky and Ohio, giving us a new strategic stronghold in the Midwest and Southern United States,” said Lou Verdetto, CEO of Strata's Clinical Division.

GlobeNewsWire • Jun 2, 2026

AIAI Holdings Corporation Announces Appointment of Board of Directors

Directors bring a strong combination of technology, healthcare, national security, leadership experience, and financial and capital markets backgrounds AIAI Expected to Begin Trading on May 14, 2026   DALLAS, TX / ACCESS Newswire / May 12, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI to enhance portfolio performance, today announced the appointment of the Company's Board of Directors. John P. Rochon leads the 10-person Board as Chairman.

Accesswire • May 12, 2026

Strata Critical Medical Announces Expiration of Warrants

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), announced that its warrants, both the Public Warrants (Nasdaq: SRTAW) and the Private Placement Warrants, expired in accordance with their original terms at 5:00 p.m. Eastern Time today May 7, 2026.

GlobeNewsWire • May 7, 2026

Strata Critical Medical Announces First Quarter 2026 Results

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the first quarter ended March 31, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only. The results of the divested Passenger business have been reclassified as discontinued operations in all periods.

GlobeNewsWire • May 6, 2026

Strata Critical Medical, Inc. (SRTA) Q1 2026 Earnings Call Transcript

Strata Critical Medical, Inc. (SRTA) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

Strata Acquires Ohio Valley Perfusion Associates

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced that it has completed the acquisition of Ohio Valley Perfusion Associates ("OVPA"), a regional provider of perfusion services to cardiac surgery programs in Ohio and Pennsylvania. “Expanding our presence in Eastern Ohio and Western Pennsylvania is an important step in strengthening Strata's regional clinical platform,” said Louis Verdetto, CEO of Strata's Clinical Services Division.

GlobeNewsWire • Apr 30, 2026

Strata Critical Medical Schedules First Quarter 2026 Earnings Conference Call

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the first quarter ended March 31, 2026 on Wednesday May 6, 2026 before the market opens.

GlobeNewsWire • Apr 20, 2026

Strata Critical Medical to Present at the 25th Annual Needham Virtual Healthcare Conference

NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 1:30 pm ET. A webcast of the event will be available at the link here.

GlobeNewsWire • Apr 9, 2026

Strata Critical Medical: Significant Upside Potential Backed By Robust EBITDA Growth

Strata Critical Medical is rated 'Buy' with a 12–24 month horizon, targeting 30–35% upside as valuation remains attractive despite a recent rally. SRTA's transformation into a pure-play medical logistics provider, robust FY25 results, and margin expansion underpin confidence in forward guidance. Industry tailwinds, regulatory catalysts, and an aggressive acquisition strategy position SRTA for sustained revenue and EBITDA growth, with FY26 guidance implying an 11.6% EBITDA margin.

Seeking Alpha • Mar 18, 2026

Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript

Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 3, 2026